Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Barnes-Jewish Hospital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 1
Average round size
info
The average size of a deal this fund participated in
$19M
Portfolio companies 1
Rounds per year 0.01
Lead investments 0
Key employees Soon

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Life Science
Summary

Barnes-Jewish Hospital appeared to be the Corporate Investor, which was created in 1902. The fund was located in North America if to be more exact in United States. The leading representative office of defined Corporate Investor is situated in the St Louis.

Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Kereos. Among the most successful fund investment fields, there are Life Science, Therapeutics.

The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2005.

The typical case for the fund is to invest in rounds with 10 participants. The meaningful sponsors for the fund in investment in the same round are Triathlon Medical Venture Partners, RiverVest, Prolog Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Barnes-Jewish Hospital:
There are no funds here. If we find new data, we will add it here.
Typical Co-investors
Barnes-Jewish Hospital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Barnes-Jewish Hospital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
&vest New York, New York, United States
BADIR Ar Riyad, Riyadh, Saudi Arabia
Cherwell Laboratories Cherwell, England, United Kingdom
ELY Center -
Geekdom Fund San Antonio, Texas, United States
K- Bridge Investment -
Kviv Ventures Brazil, São Paulo, São Paulo
The Audacious Project -
UMG IdeaLab -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Kereos

Biotechnology
Health Care
Life Science
Therapeutics
$19M20 Sep 2005 City of Saint Louis, Missouri, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Barnes-Jewish Hospital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 1
Average round size 19M
Rounds per year 0.01
Peak activity year 2005
Lead investments 0
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Kereos

Biotechnology
Health Care
Life Science
Therapeutics
$19M20 Sep 2005 City of Saint Louis, Missouri, United States
Crunchbase icon

Content report

The following text will be sent to our editors: